MIMETAS Revenue and Competitors

Claim your profile

Leiden, Netherlands

Location

N/A

Total Funding

3D

Industry

Estimated Revenue & Valuation

  • MIMETAS's estimated annual revenue is currently $22.3M per year.(i)
  • MIMETAS's estimated revenue per employee is $170,000

Employee Data

  • MIMETAS has 131 Employees.(i)
  • MIMETAS grew their employee count by -1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.7M2321%N/AN/A
#2
$32.2M17230%N/AN/A
#3
$4.4M3278%N/AN/A
#4
$4.2M31-11%N/AN/A
#5
$5.8M4323%N/AN/A
#6
$22.3M131-1%N/AN/A
#7
$42.6M23314%$31.5MN/A
#8
$2.7M2335%N/AN/A
#9
$18.4M10838%N/AN/A

High-throughput Human Disease and Tissue Models MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.

keywords:N/A

N/A

Total Funding

131

Number of Employees

$22.3M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MIMETAS News

2022-04-19 - Organs-on-chips Market Size, Scope And Forecast | CN Bio Tissues ...

CN Bio Tissues, Mimetas Insphero, Ascendance Bio, Kirkstall , Hurel , Synvivo , Axosim and Nortis. This Organs-on-chips Market report covers...

2022-04-17 - MIMETAS Participates in €325 Million Oncode-PACT Initiative to ...

LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in...

2022-04-17 - Mimetas BV participating in €325m cancer funding

Mimetas BV participating in €325m cancer funding. © Oncode Institute. 20.04.2022 by tg. Organ-on-chip disease model specialist Mimentas BV participates in a...

2019-09-14 - Global Organ-on-a-chip Market 2019 – Emulate, CN Bio ...

Emulate, CN Bio, Tissuse, Mimetas, Insphero, Ascendance Bio, Kirkstall, Hurel, Synvivo, Axosim, Nortis. Geographical Analysis: North America, ...

2019-09-13 - Massive Growth on 3D Cell Culture Market Performance ...

... Analysis, Technology and Global Industry Trends by 2027 Top Key Vendors-REPROCELL, 3D Biotek, Nano3D Biosciences, MIMETAS.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M16171%N/A
#2
$34.5M17435%N/A
#3
$35M18920%N/A
#4
$7.5M25546%N/A
#5
$46.3M36326%N/A